Table 3 Discrepant metabolites identified by GC-TOF/MS analysis between early-stage NSCLC patients and HC.

From: Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer

Peak

Similarity

Metabolite

VIP

Fold-change

1

326

3-(2-Hydroxyphenyl)propionic acid

1.50

0.81

2

279

4-Acetylbutyric acid 2

1.56

1.32

3

291

Galactonic acid

4.26

6.64

4

523

Ethanolamine

1.32

0.88

5

326

4-Androsten-19-ol-3,17-dione 1

3.67

11.59

6

789

2-Hydroxypyridine

1.10

0.83

7

814

Mannose 2

1.59

1.74

8

378

2-Deoxyerythritol

1.30

0.83

9

582

Sedoheptulose

1.28

0.77

10

780

Isoleucine

1.37

0.74

11

783

D-(glycerol-1-phosphate)

2.91

1.90

12

380

3-Hydroxybutyric acid

3.29

1.60

13

777

Aspartic acid 1

1.21

0.76

14

649

β-Glycerophosphoric acid

1.39

0.87

15

264

Prostaglandin E2 2

1.06

1.68

16

607

Glucose-1-phosphate

1.52

0.82

17

410

P-cresol

1.17

0.60

18

676

4-Aminobutyric acid 3

1.24

0.67

19

363

Lyxose 1

1.45

0.85

Back to article page